Mesoblast Added to S&P/ASX 200 INDEX
Mesoblast (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, has been added to the S&P/ASX 200 Index effective March 6, 2025.
The S&P/ASX 200 Index is Australia's premier benchmark index, designed to track the performance of the 200 largest index-eligible stocks listed on the Australian Stock Exchange (ASX) by float-adjusted market capitalization. This widely recognized index serves as the institutional investable benchmark in Australia, known for its representative, liquid, and tradable characteristics.
Mesoblast (Nasdaq:MESO; ASX:MSB), un leader globale nelle medicine cellulari allogeniche per le malattie infiammatorie, è stata aggiunta all'Indice S&P/ASX 200 a partire dal 6 marzo 2025.
L'Indice S&P/ASX 200 è il principale indice di riferimento dell'Australia, progettato per monitorare le performance delle 200 azioni più grandi idonee all'indice quotate sulla Borsa australiana (ASX), in base alla capitalizzazione di mercato rettificata per flottante. Questo indice ampiamente riconosciuto funge da benchmark investibile istituzionale in Australia, noto per le sue caratteristiche rappresentative, liquide e negoziabili.
Mesoblast (Nasdaq:MESO; ASX:MSB), un líder global en medicamentos celulares alogénicos para enfermedades inflamatorias, ha sido añadida al Índice S&P/ASX 200 a partir del 6 de marzo de 2025.
El Índice S&P/ASX 200 es el principal índice de referencia de Australia, diseñado para seguir el rendimiento de las 200 acciones más grandes elegibles para el índice que cotizan en la Bolsa de Valores de Australia (ASX), según la capitalización de mercado ajustada por flotación. Este índice ampliamente reconocido sirve como el benchmark institucional invertible en Australia, conocido por sus características representativas, líquidas y negociables.
Mesoblast (Nasdaq:MESO; ASX:MSB)는 염증 질환을 위한 동종 세포 의학의 글로벌 리더로, 2025년 3월 6일부터 S&P/ASX 200 지수에 추가되었습니다.
S&P/ASX 200 지수는 호주의 주요 벤치마크 지수로, 호주 증권 거래소(ASX)에 상장된 200개의 최대 적격 주식의 성과를 추적하도록 설계되었습니다. 이 지수는 유동성이 뛰어나고 거래 가능한 특성으로 인해 호주에서 기관 투자 가능한 벤치마크로 널리 인정받고 있습니다.
Mesoblast (Nasdaq:MESO; ASX:MSB), un leader mondial dans les médicaments cellulaires allogéniques pour les maladies inflammatoires, a été ajouté à l'Indice S&P/ASX 200 à compter du 6 mars 2025.
L'Indice S&P/ASX 200 est le principal indice de référence en Australie, conçu pour suivre la performance des 200 plus grandes actions éligibles à l'indice cotées à la Bourse australienne (ASX), en fonction de la capitalisation boursière ajustée au flottant. Cet indice largement reconnu sert de référence investissable institutionnelle en Australie, connu pour ses caractéristiques représentatives, liquides et négociables.
Mesoblast (Nasdaq:MESO; ASX:MSB), ein globaler Marktführer in der allogenen Zellmedizin für entzündliche Erkrankungen, wurde ab dem 6. März 2025 in den S&P/ASX 200 Index aufgenommen.
Der S&P/ASX 200 Index ist Australiens führender Benchmark-Index, der entwickelt wurde, um die Leistung der 200 größten indexfähigen Aktien, die an der Australian Stock Exchange (ASX) notiert sind, basierend auf der float-adjustierten Marktkapitalisierung zu verfolgen. Dieser weithin anerkannte Index dient als institutioneller investierbarer Benchmark in Australien, bekannt für seine repräsentativen, liquiden und handelbaren Eigenschaften.
- Addition to S&P/ASX 200 Index increases visibility to institutional investors
- Recognition as one of Australia's 200 largest listed companies
- Enhanced trading liquidity potential
- None.
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective March 6, 2025 on the Australian Stock Exchange (ASX).
The S&P/ASX 200 is recognized as the institutional investable benchmark in Australia. Index constituents are drawn from eligible companies listed on the ASX. The S&P/ASX 200 is designed to measure the performance of the 200 largest index-eligible stocks listed on the ASX by float-adjusted market capitalization. Representative, liquid, and tradable, it is widely considered Australia’s preeminent benchmark index.
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | Media – Global |
| Paul Hughes | Allison Worldwide |
| T: +61 3 9639 6036 | Emma Neal |
| E: investors@mesoblast.com | T: +1 603 545 4843 |
| E: emma.neal@allisonworldwide.com | |
| Media – Australia | |
| BlueDot Media | |
| Steve Dabkowski | |
| T: +61 419 880 486 | |
| E: steve@bluedot.net.au | |
FAQ
When will Mesoblast (MESO) join the S&P/ASX 200 Index?
What is the significance of Mesoblast (MESO) joining the S&P/ASX 200?
Which stock exchanges is Mesoblast (MESO) listed on?
What is Mesoblast's (MESO) main business focus?
